NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions

Advanced CancerOvarian CancerBreast CancerLung CancerEndometrial CancerOvarian NeoplasmTriple Negative Breast CancerLung NeoplasmNeoplasm MalignantColo-rectal Cancer

Interventions

DRUG

COM701

COM701 monotherapy.

DRUG

COM701 with Opdivo (Nivolumab).

COM701 in combination with Opdivo (Nivolumab).

Trial Locations (11)

10032

Columbia University, New York

34230

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute., Nashville

38138

The University of Tennessee WEST Cancer Center., Memphis

44195

Cleveland Clinic., Cleveland

49503

START Midwest., Grand Rapids

60637

University of Chicago Medical Center, Chicago

77030

M D Anderson Cancer Center., Houston

78229

The START Center for Cancer Care., San Antonio

90095

University of California Los Angeles (UCLA)., Los Angeles

02114

Massachusetts General Hospital, Boston